Econazole Nitrate Aerosol, Foam
FDA Label NDC 73352-100

Econazole nitrate topical foam, 1%, is indicated for the treatment of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes,and Epidermophyton floccosumin patients 12 years of age and older.

Econazole nitrate topical foam, 1% is for topical use only. Econazole nitrate topical foam, 1% is not for oral, ophthalmic, or intravaginal use.

Econazole nitrate topical foam, 1% should be applied to cover affected areas once daily for 4 weeks.

Foam, 1%. Each gram of econazole nitrate topical foam, 1%, contains 10 mg of econazole nitrate in a white to off-white foam.

None.

-

Econazole nitrate topical foam is flammable. Avoid heat, flame, and smoking during and immediately following application. Contents under pressure. Do not puncture and/or incinerate the containers. Do not expose containers to heat and/or store at temperatures above 120°F (49°C) even when empty. Do not store in direct sunlight.

-

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In two double-blind, vehicle-controlled clinical trials, 495 subjects were exposed to econazole nitrate topical foam or vehicle (246 subjects were exposed to econazole nitrate topical foam, 1% and 249 were exposed to vehicle). Subjects with interdigital tinea pedis applied foam or vehicle once daily for approximately 28 days. During clinical trials with econazole nitrate topical foam, the most common adverse reactions were application site reactions which occurred in less than 1% of subjects in both the econazole nitrate and vehicle arms.

-

Concomitant administration of econazole and warfarin has resulted in enhancement of anticoagulant effect. Most cases reported product application with use under occlusion, genital application, or application to a large body surface area which may increase the systemic absorption of econazole nitrate. Monitoring of International Normalized Ratio (INR) and/or prothrombin time may be indicated especially for patients who apply econazole to large body surface areas, in the genital area, or under occlusion.

-

-

Pregnancy Category C

There are no adequate and well-controlled trials with econazole nitrate topical foam in pregnant women. Econazole nitrate topical foam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Econazole nitrate has not been shown to be teratogenic when administered orally to mice, rabbits or rats. Fetotoxic or embryotoxic effects were observed in Segment I oral studies with rats receiving 10 to 40 times the human dermal dose. Similar effects were observed in Segment II or Segment III studies with mice, rabbits and/or rats receiving oral doses 80 or 40 times the human dermal dose.

It is not known whether econazole nitrate is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when econazole nitrate is administered to a nursing woman. Following oral administration of econazole nitrate to lactating rats, econazole and/or metabolites were excreted in milk and were found in nursing pups.

Of the 173 subjects treated with econazole nitrate topical foam, 1% in the clinical trials, 2 subjects were 12 to 17 years old. In a pediatric maximal use trial, econazole nitrate topical foam, 1% was applied once daily to eighteen subjects aged 12 to 17 years with interdigital tinea pedis for 28 days [ see Clinical Pharmacology (12.3)]. The safety findings for subjects 12 to 17 years were similar to those in adult population.

Of the 173 subjects treated with econazole nitrate topical foam, 1% in the adult clinical trials, 6 subjects were 65 years or older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects.

Econazole nitrate topical foam, 1% contains the azole antifungal agent, econazole nitrate in an oil-in-water emulsion base consisting of the following inactive ingredients: dimethicone, glycerin, polysorbate 20, povidone, propylene glycol, stearic acid, trolamine, purified water and butane as a propellant. Each gram of econazole nitrate topical foam, 1% contains 10 mg of econazole nitrate, USP, in a white to off-white foam. Econazola nitrate topical foam, 1% is alcohol (ethanol)-free and for topical use only.

Chemically, econazole nitrate is 1-[2-{(4-chloro-phenyl)methoxy}-2-(2,4-dichlorophenyl) ethyl]-1H-imidazole mononitrate. Econazole nitrate has the molecular formula C ₁₈H ₁₅Cl ₃N ₂O. HNO ₃and a molecular weight of 444.70. Its molecular structure is as follows:

Chemical Structure (Ecoza 01)

-

Econazole nitrate topical foam is an azole antifungal [ see Clinical Pharmacology (12.4)] .

The pharmacodynamics of econazole nitrate topical foam, 1% have not been established .

The systemic absorption of econazole nitrate topical foam, 1% following topical application was studied in one clinical trial in adults and one clinical study in pediatric subjects.

In the adult trial, 19 subjects (male and female) with tinea pedis applied econazole nitrate topical foam, 1% once daily for 29 days. Subjects applied a mean daily amount of 2.4 g of econazole nitrate topical foam, 1% to soles, toes, interdigital spaces and tops of both feet up to the ankles. Blood samples were obtained on Day 29 at pre-dose and 1, 2, 4, 6, 8, and 12 hours after application. Results (mean ± SD) showed the time to reach peak plasma concentrations (T _max) was 6.8 ± 5.1 h with maximum concentration (C _max) of 417 ± 218 pg/ml. The area under the concentration time curve for the first 12 hours post application on Day 29 (AUC _(0-12)) was 3440 ± 1920 pg-h/ml.

In the pediatric trial, 18 subjects (male and female ages 12 - 17) with interdigital tinea pedis and positive fungal cultures were treated with econazole nitrate topical foam, 1% once daily for 4 weeks. Subjects applied a mean daily amount of 3.2 g of econazole nitrate topical foam, 1% to soles, toes, interdigital spaces and tops of both feet up to the ankles. Blood samples were obtained on Day 28 at pre-dose and 7 h and 11 h post-dose. The mean ± SD econazole plasma concentration was 397 ± 289, 534 ± 745 and 575 ± 638 pg/mL at pre-dose and 7 h and 11 h post-dose, respectively.

-

Mechanism of Action

Econazole nitrate, an azole antifungal agent, inhibits fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylase enzyme. This enzyme functions to convert lanosterol to ergosterol. The accumulation of 14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell wall and may be responsible for the fungistatic activity of econazole. Mammalian cell demethylation is less sensitive to econazole inhibition.

Activity in vitroand in clinical infections

Econazole nitrate has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections [ see Indications and Usage (1)].

Trichophyton rubrum

Epidermophyton floccosum

Trichophyton mentagrophytes

Manufactured in the USA for

Trifluent Pharma, LLC
San Antonio TX 78213

-

PRODERM TECHNOLOGY ^®

U.S, Patent 5,993,830

-

Issued: 9/2025

P/N 41384

-

Long-term animal studies to determine the carcinogenic potential of econazole nitrate topical foam have not been performed.

Oral administration of econazole nitrate in rats has been reported to produce prolonged gestation.

In two multi-center, randomized, double-blind, vehicle-controlled clinical trials a total of 505 subjects with interdigital tinea pedis were randomized 1:1 to econazole nitrate topical foam or vehicle; subjects applied the assigned medication once daily for 4 weeks. The severity of erythema, scaling, fissuring, maceration, vesiculation, and pruritus were graded using a 4-point scale (none, mild, moderate, severe). Subjects had KOH examination and fungal cultures taken to confirm eligibility. A total of 339 subjects with positive fungal cultures were evaluated for efficacy. Efficacy was evaluated on Day 43, 2 weeks post-treatment with treatment success being defined as complete cure (negative KOH and fungal culture and no evidence of clinical disease). The study population ranged in age from 12 to 71 years with 5 subjects less than 18 years of age at baseline. The subjects were 71% male and 51% Caucasian. Table 1 presents the efficacy results for each trial.

^aMycological cure and an absence of clinical signs and symptoms (erythema, scaling, fissuring, maceration, vesiculation, or pruritus).
^bMycological cure and no or mild erythema and/or scaling with all other signs and symptoms absent.
^cNegative KOH and fungal culture.

Econazole nitrate topical foam, 1% is white to off-white foam supplied in 70g (NDC 73352-100-70) aluminum pressurized canister.

Store at controlled room temperature 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C and 30°C (59°F and 86°F). Do not refrigerate or freeze.

Econazole nitrate topical foam is flammable. Avoid heat, flame, and smoking during and immediately following application.

Contents under pressure. Do not puncture and/or incinerate the containers.

Do not expose containers to heat and/or store at temperatures above 120°F (49°C) even when empty.

Do not store in direct sunlight.

See FDA-approved patient labeling (Patient Information)

The patient should be instructed as follows:

• Inform patients that econazole nitrate topical foam, 1% is for topical use only. Econazole nitrate topical foam, 1% is not intended for oral, intravaginal, or ophthalmic use.
• Econazole nitrate topical foam, 1% is flammable; avoid heat, flame, and smoking during and immediately following application.
• If a reaction suggesting sensitivity or chemical irritation develops with the use of econazole nitrate topical foam, 1%, use of the medication should be discontinued.

Parts of econazole nitrate topical foam Canister. (See Figure A)

Container (Can)

Figure A

How to apply econazole nitrate topical foam:

Figure B (Ecoza 03)	Figure C (Ecoza 04)
Figure B	Figure C

Step 4:	Use your finger-tips to scoop up small amounts of econazole nitrate topical foam and apply to the affected skin areas on your feet. Gently rub the foam into the skin. (See Figure D)
Figure D (Ecoza 05)
Figure D
Step 5:	You should apply econazole nitrate topical foam to your toes, to the spaces between your toes, and to the surrounding areas 1 time a day for 4 weeks or as prescribed by your doctor.
Step 6:	Replace the cap. Wash your hands after applying econazole nitrate topical foam.

How should I store econazole nitrate topical foam?

• Store econazole nitrate topical foam at room temperature, between 68°F to 77°F (20°C to 25°C).
• Do not refrigerate or freeze econazole nitrate topical foam.
• Do not store econazole nitrate topical foam in direct sunlight.
• Econazole nitrate topical foam is flammable. Keep the econazole nitrate topical foam canister away from heat and temperatures above 120°F (49°C), even if the canister is empty.
• Do not puncture or burn the econazole nitrate topical foam canister.

Keep econazole nitrate topical foam and all medicines out of the reach of children.

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

Manufactured for Trifluent Pharma, LLC, San Antonio, TX 78213

Issued: 09/2025

NDC 73352-100-70

Econazole nitrate topical foam, 1%

For Topical Use Only

Not for ophthalmic, oral or intravaginal use.

Keep Out of Reach of Children

Rx Only
Net Wt 70g